Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia - PubMed (original) (raw)
Clinical Trial
doi: 10.1038/leu.2008.5. Epub 2008 Jan 31.
A Schrauder, G Cazzaniga, R Panzer-Grümayer, V van der Velden, S Fischer, M Stanulla, G Basso, F K Niggli, B W Schäfer, R Sutton, R Koehler, M Zimmermann, M G Valsecchi, H Gadner, G Masera, M Schrappe, J J M van Dongen, A Biondi, C R Bartram; International BFM Study Group (I-BFM-SG)
Affiliations
- PMID: 18239620
- DOI: 10.1038/leu.2008.5
Clinical Trial
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia
T Flohr et al. Leukemia. 2008 Apr.
Abstract
Detection of minimal residual disease (MRD) is the most sensitive method to evaluate treatment response and one of the strongest predictors of outcome in childhood acute lymphoblastic leukemia (ALL). The 10-year update on the I-BFM-SG MRD study 91 demonstrates stable results (event-free survival), that is, standard risk group (MRD-SR) 93%, intermediate risk group (MRD-IR) 74%, and high risk group (MRD-HR) 16%. In multicenter trial AIEOP-BFM ALL 2000, patients were stratified by MRD detection using quantitative PCR after induction (TP1) and consolidation treatment (TP2). From 1 July 2000 to 31 October 2004, PCR target identification was performed in 3341 patients: 2365 (71%) patients had two or more sensitive targets (< or =10(-4)), 671 (20%) patients revealed only one sensitive target, 217 (6%) patients had targets with lower sensitivity, and 88 (3%) patients had no targets. MRD-based risk group assignment was feasible in 2594 (78%) patients: 40% were classified as MRD-SR (two sensitive targets, MRD negativity at both time points), 8% as MRD-HR (MRD > or =10(-3) at TP2), and 52% as MRD-IR. The remaining 823 patients were stratified according to clinical risk features: HR (n=108) and IR (n=715). In conclusion, MRD-PCR-based stratification using stringent criteria is feasible in almost 80% of patients in an international multicenter trial.
Comment in
- Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-kappa and heavy-chain gene rearrangements.
Sutton R, Bahar AY, Kwan E, Giles JE, Venn NC, Tran S, Hackenberg N, Pozza LD, Marshall GM, Haber M, van der Velden VH, Norris MD. Sutton R, et al. Leukemia. 2008 Dec;22(12):2265-7. doi: 10.1038/leu.2008.121. Epub 2008 May 22. Leukemia. 2008. PMID: 18496559 No abstract available.
Similar articles
- Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia.
Cui L, Li Z, Wu M, Li W, Gao C, Deng G. Cui L, et al. Leuk Res. 2010 Oct;34(10):1314-9. doi: 10.1016/j.leukres.2009.11.031. Epub 2010 Jan 19. Leuk Res. 2010. PMID: 20034668 - [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H. zur Stadt U, et al. Klin Padiatr. 2000 Jul-Aug;212(4):169-73. doi: 10.1055/s-2000-9672. Klin Padiatr. 2000. PMID: 10994545 Clinical Trial. German. - Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
Kolenova A, Hikkel I, Ilencikova D, Hikkelova M, Sejnova D, Kaiserova E, Cizmar A, Puskacova J, Bubanska E, Oravkinova I, Gencik M. Kolenova A, et al. Neoplasma. 2010;57(6):552-61. doi: 10.4149/neo_2010_06_552. Neoplasma. 2010. PMID: 20845994 - Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
Szczepański T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ. Szczepański T, et al. Best Pract Res Clin Haematol. 2002 Mar;15(1):37-57. doi: 10.1053/beha.2002.0184. Best Pract Res Clin Haematol. 2002. PMID: 11987915 Review. - Detection of minimal residual disease in acute leukemia.
van der Velden VH, Boeckx N, van Wering ER, van Dongen JJ. van der Velden VH, et al. J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):146-54. J Biol Regul Homeost Agents. 2004. PMID: 15471219 Review.
Cited by
- Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?
Stutterheim J, van der Waarden R, de Groot-Kruseman HA, Sonneveld E, de Haas V, Dandis R, van der Schoot CE, van der Velden VHJ, Pieters R. Stutterheim J, et al. Leukemia. 2024 Sep 10. doi: 10.1038/s41375-024-02386-5. Online ahead of print. Leukemia. 2024. PMID: 39256602 - Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines.
van der Velden VHJ, Dombrink I, Alten J, Cazzaniga G, Clappier E, Drandi D, Eckert C, Fronkova E, Hancock J, Kotrova M, Kraemer R, Montonen M, Pfeifer H, Pott C, Raff T, Trautmann H, Cavé H, Schäfer BW, van Dongen JJM, Trka J, Brüggemann M; EuroMRD Consortium. van der Velden VHJ, et al. Leukemia. 2024 Jun;38(6):1315-1322. doi: 10.1038/s41375-024-02272-0. Epub 2024 May 14. Leukemia. 2024. PMID: 38744919 Free PMC article. - A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL.
Popov A, Henze G, Roumiantseva J, Bydanov O, Belevtsev M, Verzhbitskaya T, Movchan L, Tsaur G, Lagoyko S, Zharikova L, Myakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Cancers (Basel). 2023 Nov 23;15(23):5547. doi: 10.3390/cancers15235547. Cancers (Basel). 2023. PMID: 38067249 Free PMC article. - Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.
Chen H, Gu M, Liang J, Song H, Zhang J, Xu W, Zhao F, Shen D, Shen H, Liao C, Tang Y, Xu X. Chen H, et al. Nat Commun. 2023 Nov 17;14(1):7468. doi: 10.1038/s41467-023-43171-9. Nat Commun. 2023. PMID: 37978187 Free PMC article. - Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.
Ronceray L, Dworzak M, Dieckmann K, Ebetsberger-Dachs G, Glogova E, Haas OA, Jones N, Nebral K, Moser R, Lion T, Meister B, Panzer-Grümayer R, Strehl S, Peters C, Pötschger U, Urban C, Mann G, Attarbaschi A; Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Ronceray L, et al. Wien Klin Wochenschr. 2024 Jul;136(13-14):405-418. doi: 10.1007/s00508-023-02249-6. Epub 2023 Aug 3. Wien Klin Wochenschr. 2024. PMID: 37535134
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials